ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Authors: Severine Vermeire, Bruce E Sands, Herbert Tilg, Zsolt Tulassay, Radoslaw Kempinski, Silvio Danese, Ivan Bunganič, Josianne Nitcheu, Julien Santo, Didier Scherrer, Sophie Biguenet, Hartmut J Ehrlich, Jean-Marc Steens, Paul Gineste, William J Sandborn

Published: 2022-09-06

DOI: 10.1016/s2468-1253(22)00233-3

Source: Full article

---

Abstract

No abstract found.